Synergism of simvastatin with losartan prevents angiotensin II-induced cardiomyocyte apoptosis in vitro

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 4, 2009, Pages 503-510

  Xu, Jian ^a,b   Lü, Xiong Wen ^a   Huang, Yan ^a   Zhu, Peng Li ^a   Li, Jun ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

Angiotensin II; Bax; Bcl 2; Cardiomyocyte apoptosis; Losartan; Simvastatin

Indexed keywords

ANGIOTENSIN II; LOSARTAN; PROTEIN BAX; PROTEIN BCL 2; SIMVASTATIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL VIABILITY; COCULTURE; CONTROLLED STUDY; DRUG POTENTIATION; EVALUATION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HEART FAILURE; HEART MUSCLE CELL; IN VITRO STUDY; INCIDENCE; NONHUMAN; PROTEIN EXPRESSION; RAT; ANIMAL; CELL SURVIVAL; CULTURE TECHNIQUE; CYTOLOGY; DRUG EFFECT; METABOLISM; NEWBORN;

ANGIOTENSIN II; ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL CULTURE TECHNIQUES; CELL SURVIVAL; DRUG SYNERGISM; LOSARTAN; MYOCYTES, CARDIAC; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; SIMVASTATIN;

EID: 66449122174     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp/61.04.0013     Document Type: Article

References (35)

1. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007; 35: 495-516.
2. Fadeel B, Orrenius S. Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease. J Intern Med 2005; 258: 479-517.
3. Li Z et al. Increased cardiomyocyte apoptosis during the transition to heart failure in the spontaneously hypertensive rat. Am J Physiol 1997; 272: H2313-2319.
4. Wencker D et al. A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest 2003; 111: 1497-1504.
5. Abbate A et al. Pathophysiologic role of myocardial apoptosis in post-infarction left ventricular remodeling. J Am Coll Cardiol 2002; 193: 145-153.
6. Li PF et al. p53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c-independent apoptosis blocked by bcl-2. EMBO J 1999; 21: 6027-6036.
7. Condorelli G et al. Increased cardiomyocyte apoptosis and changes in proapoptotic and antiapoptotic genes bax and bcl-2 during left ventricular adaptations to chronic pressure overload in the rat. Circulation 1999; 99: 3071-3078.
8. Xu J et al. Role of cardiac overexpression of Ang II in the regulation of cardiac function and remodeling postmyocardial infarction. Am J Physiol Heart Circ Physiol 2007; 293: H1900-1907.
9. Li HL et al. Overexpression of myofibrillogenesis regulator-1 aggravates cardiac hypertrophy induced by angiotensin II in mice. Hypertension 2007; 49: 1399-1408.
10. Ono H, Ishimitsu T Effects of angiotensin II type 1 and type 2 receptor on apoptosis. Nippon Rinsho 2002; 60: 1887-1892.
11. Yamada T et al. Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad SciUSA 1996; 93: 156-160.
12. Kajstura J et al.Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol 1997; 29: 859-870.
13. Zhu YC et al. Role of angiotensin AT1 and AT2 receptors in cardiac hypertrophy and cardiac remodelling. Clin Exp Pharmacol Physiol 2003; 30: 911-918.
14. Simonis G et al. A novel activation process of protein kinase C in the remote, non-ischemic area of an infarcted heart is mediated by angiotensin-AT1 receptors. J Mol Cell Cardiol 2003; 35: 1349-1358.
15. Anavekar NS, Solomon SD. Angiotensin II receptor blockade and ventricular remodelling. J Renin Angiotensin Aldosterone Syst 2005; 6: 43-48.
16. Shimizu T et al. Long-term combined therapy with an angiotensin type I receptor blocker and an angiotensin converting enzyme inhibitor prolongs survival in dilated cardiomyopathy. Jpn Heart J 2002; 43: 531-543.
17. Suzuki G et al. Effects of the AT1 receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure. Br J Pharmacol 2003; 138: 301-309.
18. Bauersachs J et al. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 2001; 104: 982-985.
19. Hognestad A et al., OPTIMAAL Investigators. Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure. Am J Cardiol 2004; 93: 603-606.
20. Landmesser U et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 2004; 110: 1933-1939.
21. Dickstein K, Kjekshus J, the OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial: Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360: 752-760.
22. Laufs U et al. Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovasc Res 2002; 53: 911-920.
23. Maack C et al. Oxygen free-radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 2003; 108: 1567-1574.
24. Nickenig G et al. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999; 100: 2131-2134.
25. Tang SC et al. Angiotensin converting enzyme inhibitor but not angiotensin receptor blockade or statin ameliorates murine adriamycin nephropathy. Kidney Int 2008; 73: 288-299.
26. Goldenberg I et al. Adenosine protects against angiotensin II-induced apoptosis in rat cardiocyte cultures. Mol Cell Biochem 2003; 252: 133-139.
27. Xie HH et al. Synergism of atenolol and nitrendipine on hemodynamic amelioration and organ protection in hypertensive rats. J Hypertens 2005; 23: 193-201.
28. Wang J et al. Effects of nine antihypertensive drugs on blood pressure variability in sinoaortic-denervated rats. Acta Pharmacol Sin 2006; 27: 1013-1017.
29. Pang JJ et al. Hexarelin protects rat cardiomyocytes from angiotensin II-induced apoptosis in vitro. Am J Physiol Heart Circ Physiol 2004; 286: H1063-1069.
30. Mel'nikova NP et al. Angiotensin-II activates apoptosis, proliferation and protein synthesis in the left heart ventricle of newborn albino rats. Int J Cardiol 2006; 112: 219-222.
31. Jin ZJ. Addition in drug combination. Acta Pharmacol Sin 1980; 1: 70-76.
32. Han P et al. Synergism of hydrochlorothiazide and nitrendipine on reduction of blood pressure and blood pressure variability in spontaneously hypertensive rats. Acta Pharmacol Sin 2006; 27: 1575-1579.
33. Ling G et al. Effects of combination therapy with atenolol and amlodipine on blood pressure control and stroke prevention in stroke-prone spontaneously hypertensive rats. Acta Pharmacol Sin 2007; 28: 1755-1760.
34. Wassmann S et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol 2001; 59: 646-654.
35. Luo JD et al. Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clin Exp Pharmacol Physiol 1999; 26: 903-908.